Mineralys Therapeutics, Inc. (NasdaqGS: MLYS)
Health Care · Biotechnology · US
$25.89
+0.98% today · +67.1% 1Y
Mineralys Therapeutics, Inc. (NasdaqGS: MLYS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.27B and employs 76 people.
Over the last twelve months the share price has gained 67.1%, trading between 14.16 and 47.65.
Tweenvest scores Mineralys Therapeutics, Inc. across four factors: quality 28/100. Its strongest factor is quality.
MLYS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.27B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.38
- Dividend yield
- —
- Beta (5Y)
- 0.68
- 52-week high
- $47.65
- 52-week low
- $14.16
- Avg volume (3M)
- —
- Shares outstanding
- 88.41M
- Employees
- 76
- Next earnings
- —
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
- ISIN
- US6031701013
- Founded
- 2019
- Listed since
- Feb 10, 2023
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.